Nippon Kayaku Co., Ltd.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1916-06-05
- Employees
- 5.9K
- Market Cap
- -
A Phase III Study of NK105 in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 436
- Registration Number
- NCT01644890
- Locations
- π―π΅
Japan Sites, Tokyo, Etc., Japan
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT01475266
- Locations
- π―π΅
Nippon Kayaku Investigational site 107, Kashihara, Nara, Japan
π―π΅Nippon Kayaku Investigational site 110, Fukuoka, Japan
π―π΅Nippon Kayaku Investigational site 103, Yokosuka, Kanagawa, Japan
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
- Conditions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT01238952
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01238939
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01052259
- Locations
- π―π΅
Gifu University Graduate School of Medicine, Gifu, Japan
π―π΅Graduate School of Medicine Sciences, Kyushu University, Fukuoka, Japan
π―π΅Sapporo City General Hospital, Sapporo, Hokkaido, Japan
A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT00951613
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
- Conditions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT00951054
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT00709722
- Locations
- π©πͺ
Universitat Frankfurt, Frankfurt, Germany
π©πͺUniversity of Regensburg, Regensburg, Germany
π©πͺUniversity Hospital Mannheim, Heidelberg University, Mannheim, Germany
Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT00628121
- Locations
- π―π΅
Kitasato University East Hospital, Sagamihara, Kanagawa, Japan
Study of NK012 in Patients With Refractory Solid Tumors
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT00542958
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Nashville, Tennessee, United States